Education
About Us
Working with TipRanks
Follow Us
Werewolf Therapeutics (HOWL)
NASDAQ:HOWL
HOWL Analyst Ratings
Moderate Buy
2 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
HOWL Stock 12 Month Forecast
Average Price Target
$8.50
▲(725.24% Upside)
| Highest Price Target$10.00 | Average Price Target$8.50 | Lowest Price Target$7.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Bank of America Securities
$8→$7
Buy
579.61%
Upside
Reiterated
11/18/25
H.C. Wainwright
$10
Buy
870.87%
Upside
Reiterated
09/17/25
Leerink Partners
$12→$10
Buy
870.87%
Upside
Reiterated
09/04/25
We believe 2H25 expansion cohorts could demonstrate meaningful WTX-124 monotherapy activity and added benefit in combination with pembrolizumab—especially in cutaneous melanoma, where we are particularly encouraged by management's reiteration that they see a path for monotherapy approval. However, the bar for excitement is high—20-30% confirmed overall response rates in 20-30 patients—given persistent investor skepticism toward IO mechanisms. Longer- term, we see potential for masked CD3 T-cell engagers (TCEs) to drive value for Werewolf. We are encouraged by recent progress applying the PREDATOR platform to TCEs, and view STEAP1 as an attractive lead target. We reiterate our Outperform and lower our price target (PT) to $10 (from $12) following updates for 2Q25 results and company guidance.
Citizens JMP
$4→$3
Buy
191.26%
Upside
Reiterated
08/21/25
Jefferies
$11→$4
Buy
288.35%
Upside
Initiated
08/04/25
Wedbush
$8→$6
Buy
482.52%
Upside
Reiterated
05/09/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Bank of America Securities
$8→$7
Buy
579.61%
Upside
Reiterated
11/18/25
H.C. Wainwright
$10
Buy
870.87%
Upside
Reiterated
09/17/25
Leerink Partners
$12→$10
Buy
870.87%
Upside
Reiterated
09/04/25
We believe 2H25 expansion cohorts could demonstrate meaningful WTX-124 monotherapy activity and added benefit in combination with pembrolizumab—especially in cutaneous melanoma, where we are particularly encouraged by management's reiteration that they see a path for monotherapy approval. However, the bar for excitement is high—20-30% confirmed overall response rates in 20-30 patients—given persistent investor skepticism toward IO mechanisms. Longer- term, we see potential for masked CD3 T-cell engagers (TCEs) to drive value for Werewolf. We are encouraged by recent progress applying the PREDATOR platform to TCEs, and view STEAP1 as an attractive lead target. We reiterate our Outperform and lower our price target (PT) to $10 (from $12) following updates for 2Q25 results and company guidance.
Citizens JMP
$4→$3
Buy
191.26%
Upside
Reiterated
08/21/25
Jefferies
$11→$4
Buy
288.35%
Upside
Initiated
08/04/25
Wedbush
$8→$6
Buy
482.52%
Upside
Reiterated
05/09/25
Best Analysts Covering Werewolf Therapeutics
1 Month
xxx
Success Rate
12/20 ratings generated profit
Average Return
+3.06%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 60.00% of your transactions generating a profit, with an average return of +3.06% per trade.
3 Months
xxx
Success Rate
8/17 ratings generated profit
Average Return
-4.59%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 47.06% of your transactions generating a profit, with an average return of -4.59% per trade.
1 Year
Success Rate
4/14 ratings generated profit
Average Return
-3.42%
reiterated a buy rating 29 days ago
Copying Jason Zemansky's trades and holding each position for 1 Year would result in 28.57% of your transactions generating a profit, with an average return of -3.42% per trade.
2 Years
xxx
Success Rate
3/17 ratings generated profit
Average Return
-40.76%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 17.65% of your transactions generating a profit, with an average return of -40.76% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
HOWL Analyst Recommendation Trends
Rating
Jul 25
Aug 25
Sep 25
Oct 25
Nov 25
Strong Buy
5
4
6
6
3
Buy
0
0
0
0
0
Hold
7
10
5
4
2
Sell
3
0
0
1
2
Strong Sell
0
0
0
0
0
total
15
14
11
11
7
Each month's total comprises the sum of three months' worth of ratings.
HOWL Financial Forecast
HOWL Stock Forecast FAQ
What is HOWL’s average 12-month price target, according to analysts?
Based on analyst ratings, Werewolf Therapeutics’s 12-month average price target is 8.50.
What is HOWL’s upside potential, based on the analysts’ average price target?
Werewolf Therapeutics has 725.24% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is HOWL a Buy, Sell or Hold?
Werewolf Therapeutics has a consensus rating of Moderate Buy which is based on 2 buy ratings, 0 hold ratings and 0 sell ratings.
What is Werewolf Therapeutics’s price target?
The average price target for Werewolf Therapeutics is 8.50. This is based on 2 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $10.00 ,the lowest forecast is $7.00. The average price target represents 725.24% Increase from the current price of $1.03.
The highest analyst price target is $10.00 ,the lowest forecast is $7.00. The average price target represents 725.24% Increase from the current price of $1.03.
What do analysts say about Werewolf Therapeutics?
Werewolf Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 2 Wall Streets Analysts.
How can I buy shares of HOWL?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.